Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dapagliflozin tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

NCT01662999
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Saxagliptin, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment

NCT00663260
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
34
States / cities
Mesa, Arizona • Fresno, California • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 20, 2026, 7:09 PM EDT
Suspended Phase 4 Interventional Accepts healthy volunteers

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

NCT05435235
View directory record Official record
Conditions
Acute Kidney Injury, Percutaneous Coronary Intervention
Interventions
Dapagliflozin 10mg Tab
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dapagliflozin In Alzheimer's Disease

NCT03801642
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Jeff Burns, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

Add-on to Thiazolidinedione (TZD) Failures

NCT00683878
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin, Thiazolidinedione (Pioglitazone)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
972 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
57
States / cities
Anniston, Alabama • Ozark, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 20, 2026, 7:09 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

NCT03660683
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
30 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 4 Interventional

The Fontan Dapagliflozin Pilot Study

NCT05741658
View directory record Official record
Conditions
Heart Failure
Interventions
Dapagliflozin 10mg Tab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

NCT00643851
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

NCT00930865
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bumetanide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

NCT00839683
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
simvastatin, Dapagliflozin, valsartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

NCT02547935
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions
Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Peoria, Arizona • Chula Vista, California • Concord, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

NCT02981966
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

NCT02413398
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 74 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Huntsville, Alabama • Burbank, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

NCT01619059
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Dapagliflozin, Metformin IR, Placebo matching with Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
34
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Sep 20, 2026, 7:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

NCT05719714
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

NCT03619213
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
6,263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
66
States / cities
Fairhope, Alabama • Mobile, Alabama • Sheffield, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 20, 2026, 7:09 PM EDT
Active, not recruiting Phase 3 Interventional

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

NCT04333823
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Dapagliflozin 5mg, Placebo
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
12 Years to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Results available

PK Study of Dapagliflozin in Pediatric Subjects With T2DM

NCT01525238
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 20, 2026, 7:09 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

NCT02520518
View directory record Official record
Conditions
Weight Loss
Interventions
Dapagliflozin, Placebo, Weight maintenance, Ad libitum dietary intake, Dietary restriction
Drug · Behavioral
Lead sponsor
Christopher Bell
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

NCT03877224
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 150 Years
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
25
States / cities
Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

Dapagliflozin Effects on Hypoglycemia

NCT03704818
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Dapagliflozin 5mg, Placebo Oral Tablet
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

NCT03036150
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
55
States / cities
Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 20, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

NCT00831779
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
San Diego, California • Baton Rouge, Louisiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 20, 2026, 7:09 PM EDT